SETYAWAN, Y. Nilotinib as the First Line Therapy in Managing Chronic Myelogenous Leukemia. e-CliniC, [S. l.], v. 9, n. 2, p. 342–350, 2021. DOI: 10.35790/ecl.v9i2.32699. Disponível em: https://ejournal.unsrat.ac.id/v3/index.php/eclinic/article/view/32699. Acesso em: 26 apr. 2024.